查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2158675

良性攝護腺增生治療市場：全球市場預測，2026-2032年

Benign Prostatic Hypertrophy Medication Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，良性前列腺增生 (BPH) 治療市場將成長至 131.5 億美元，複合年成長率為 6.28%。

主要市場統計數據
基準年 2025 85.8億美元
預計年份：2026年 91.6億美元
預測年份 2032 131.5億美元
複合年成長率 (%) 6.28%

良性前列腺增生（BPH）治療藥物：概述

良性攝護腺增生（BPH），也常被稱為良性攝護腺增生症，是一種非癌性疾病，其特徵是攝護腺增大，阻塞尿流並引起下泌尿道症狀。藥物治療仍是重要的治療選擇，尤其適用於症狀較輕微至中度的患者、攝護腺增大的患者或疾病進展風險較高的患者。治療方案的選擇取決於症狀的嚴重程度、前列腺的特徵、合併症、對副作用的耐受性以及患者的意願。常用的藥物治療包括α-腎上腺素受體阻斷劑、5α-還原酶抑制劑、5型磷酸二酯酶抑制劑和聯合治療，但治療途徑還包括後續觀察、生活方式調整、微創手術和外科手術。

治療格局正在向個人化、長期照護轉變。

治療方法正從單純的症狀抑制轉向個體化的長期管理。臨床醫生擴大將前列腺體積、前列腺特異性抗原（PSA）水平、尿流率、殘餘尿量、症狀評分和治療反應作為指南，以區分快速緩解症狀和降低疾病進展風險。聯合治療可以針對互補的作用機制，但也可能增加治療的​​複雜性，並引發對副作用的擔憂。因此，以患者為中心的決策至關重要，尤其是在性功能障礙、頭暈、血壓變化或治療的連續性影響患者用藥依從性的情況下。早期發現症狀加重並建立更清晰的轉診途徑，也有助於及時評估閉尿症、反覆性行為感染、血尿、腎功能障礙或疑似惡性腫瘤等情況。

人工智慧可以提高診斷水平、藥物依從性和護理協調能力。

人工智慧 (AI) 可以透過簡化症狀調查問卷、識別疾病進展風險患者、輔助解讀尿流率和影像學結果以及改進臨床試驗參與者招募，來支持良性前列腺增生 (BPH) 的診療。預測工具與檢驗的臨床數據結合，可以幫助臨床醫生比較不同藥物治療方案的預期效益和副作用風險。數位提醒和遠端症狀追蹤可以提高患者的用藥依從性，並有助於及早發現治療失敗。然而，人工智慧只能作為一種輔助工具。其輸出結果需要經過臨床檢驗、透明的資料管治、敏感健康資訊的保護以及防止人口統計和社會經濟偏見的安全措施。證據必須證明患者預後得到改善，而不能僅依賴技術上的準確性。

區域概況：在醫療服務取得、診斷和治療能力方面存在顯著差異。

在北美，基層醫療、泌尿系統服務、處方藥和微創治療的普及程度普遍較高，但經濟負擔、保險體系設計以及專科醫生的可近性仍然是重要的考量。在歐洲，既有完善的臨床指南，也有多種不同的報銷制度，各國的醫療服務可近性也存在差異。亞太地區擁有高度發展的醫療保健體系，都市區快速擴張，專科醫生數量也較多，但人口老化和就醫行為的差異往往會影響診斷。在拉丁美洲，公共部門資源、藥品可近性和專科醫生覆蓋範圍存在差異，因此基層醫療方案和學名藥的可近性至關重要。中東的特點是專科醫生集中在主要都市區，且報銷制度因地區而異。在非洲，由於診斷基礎設施不足、專科醫生短缺、就醫延遲以及藥品費用負擔沉重等因素，存在大量未滿足的醫療需求，因此，可擴展的基層醫療篩檢和轉診系統尤為重要。

針對特定群體的見解：政策一致性和醫療保健系統結構是採納的關鍵因素。

東協成員國在醫療保健融資、監管和專科體系方面面臨不同的情況，需要靈活的治療方案和可靠的藥品供應。金磚國家雖然擁有龐大的患者群體，但在公共醫療保險覆蓋範圍、國內藥品生產和採購以及都市區醫療服務可及性方面存在顯著差異。歐盟在科學和監管方面共用合作，但在報銷制度和服務提供方面仍存在國家差異。七國集團（G7）的醫療保健體系通常擁有成熟的診斷和藥理學能力，但必須應對人口老化、多重用藥、治療依從性和成本效益等挑戰。海灣合作理事會（GCC）國家的專科醫療服務通常相對集中，都市區基礎設施完善，但醫療專業人員的分佈以及對進口藥品的依賴可能會影響醫療服務的連續性。北約成員國的醫療保健體系各不相同，它們繼續優先考慮臨床指南的互通性、藥品供應的穩定性以及應對跨境醫療壓力的能力。

各國情況：不同的國家情況造就了不同的優先事項。

澳洲和加拿大需要覆蓋廣闊的地域，同時確保民眾能夠及時獲得基層醫療和泌尿系統服務。巴西和墨西哥在公共醫療服務、診斷和藥物供應方面面臨區域差異。中國和印度人口眾多且老化嚴重，因此優先考慮標準化診斷、分級轉診系統以及在主要城市以外地區擴大醫療服務覆蓋範圍。日本和韓國擁有先進的醫療基礎設施，且人口老化程度較高，因此優先考慮治療的連續性、多重用藥以及生活品質（QOL）結果。法國、德國、義大利和西班牙均在成熟的歐洲醫療體系內運作，但在保險報銷、處方習慣和等待時間方面存在差異。英國強調以指引為基礎的醫療和基層醫療管理，同時兼顧轉診能力。美國提供多種治療和手術選擇，但保險覆蓋範圍、自付費用以及醫療服務分散化可能會影響治療選擇。俄羅斯在區域醫療服務覆蓋、供應連續性和專科醫生資源方面面臨著獨特的挑戰。在所有國家，臨床醫生都必須區分良性攝護腺增生（BPH）的症狀與感染疾病。

優先考慮實證醫療服務、藥物依從性和綜合護理。

產業領導者應支持對老年合併症患者俱有臨床意義且實證的療法，這些療法應能改善症狀管理、尿流、降低疾病進展風險、提高生活品質、確保治療的連續性和安全性。以病人為中心的包裝、簡單易懂的教育、用藥依從性支持以及協作決策工具可以促進合理用藥，避免鼓勵不必要的治療。各機構應與醫療系統合作，加強基層醫療流程、轉診標準、藥物安全監測和供應連續性，同時根據當地的報銷機制和監管要求調整實施方案。只有在確保終點指標檢驗、人工監督、網路安全措施和透明的績效監測的情況下，才能實施數位化和人工智慧驅動的服務。取得夥伴關係應包括負責任的學名藥競爭、公平分配以及建立合作夥伴關係，以改善服務不足地區的診斷和治療能力。

調查方法：基於證據的市場評估

本執行摘要採用結構化審查框架，重點關注良性前列腺增生 (BPH) 藥物的臨床和醫療保健系統方面。評估內容包括：既定的疾病管理路徑、公認的治療分類、病患選擇因素、安全性和依從性挑戰、診斷要求、監管和報銷環境，以及特定地區、人口和國家在醫療保健服務取得方面的差異。研究結果以定性方式呈現，避免涉及市場規模和估算、市場規模計算、市場佔有率、預測以及未經證實的公司特定聲明。如果臨床指南、比較證據、安全性資訊和國家准入政策發生變化，則應更新解讀。

機會在於更協作和以病人為中心的良性前列腺增生症管理。

良性前列腺增生 (BPH) 的藥物治療若能融入更廣泛的治療路徑，結合精準評估、個人化處方、監測和及時強化治療，則療效最佳。關鍵優先事項包括改善診斷、維持用藥依從性、控制副作用以及減少初級和專科醫療服務取得的不平等。由於地區和國家差異，需要靈活實施，而非採用單一的全球模式。能夠將可靠的臨床證據與負責任的數位化創新、可靠的供應鏈以及跨醫療系統協作相結合的領導者，將有助於提供更安全、更持續、更以患者為中心的醫療服務。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 良性攝護腺增生治療市場：依產品類型分類

  • 5α-還原酶抑制劑
    • 度他雄胺
    • 非那雄胺
  • α受體阻斷劑
    • 阿夫唑嗪
    • 多沙唑嗪
    • Tamsulosin
    • 特拉唑嗪
  • 聯合治療
    • 度他雄胺Tamsulosin
    • 非那雄胺Tamsulosin

第8章 良性攝護腺增生治療藥物市場：依藥物類型分類

  • 品牌
  • 非專利的

第9章 良性攝護腺增生（BPH）治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章 良性攝護腺增生治療市場：依年齡層別分類

  • 45-64歲
  • 65歲或以上
  • 45歲以下

第11章 良性攝護腺增生治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 良性攝護腺增生（BPH）治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 良性攝護腺增生（BPH）治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Ferring Pharmaceuticals
  • GlaxoSmithKline plc
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

第16章 主要專家

Product Code: MRR-4654A89DBB7C

The Benign Prostatic Hypertrophy Medication Market is projected to grow by USD 13.15 billion at a CAGR of 6.28% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.58 billion
Estimated Year [2026] USD 9.16 billion
Forecast Year [2032] USD 13.15 billion
CAGR (%) 6.28%

Benign Prostatic Hypertrophy Medication: Executive Overview

Benign prostatic hypertrophy (BPH), commonly termed benign prostatic hyperplasia, is a noncancerous enlargement of the prostate that can obstruct urine flow and produce lower urinary tract symptoms. Medication remains an important management option, particularly for patients with mild to moderate symptoms, enlarged prostates, or elevated risk of progression. Treatment selection depends on symptom severity, prostate characteristics, comorbidities, adverse-effect tolerance, and patient preferences. Common pharmacological approaches include alpha-adrenergic blockers, 5-alpha-reductase inhibitors, phosphodiesterase-5 inhibitors, and combination regimens, while treatment pathways also include monitoring, lifestyle measures, minimally invasive procedures, and surgery.

Treatment Pathways Are Shifting Toward Personalized, Longitudinal Care

The treatment landscape is moving beyond symptom suppression toward individualized, longitudinal management. Clinicians increasingly distinguish between rapid symptom relief and reduction of disease progression risk, using prostate volume, prostate-specific antigen levels, urinary flow, residual urine, symptom scores, and treatment response to guide decisions. Combination therapy can address complementary mechanisms but may increase complexity and adverse-effect concerns. Shared decision-making is therefore central, especially when sexual dysfunction, dizziness, blood-pressure effects, or treatment persistence influence adherence. Earlier identification of worsening symptoms and clearer referral pathways also support timely evaluation for urinary retention, recurrent infection, hematuria, renal impairment, or suspected malignancy.

Artificial Intelligence Can Strengthen Diagnosis, Adherence, and Care Coordination

Artificial intelligence can support BPH care by organizing symptom questionnaires, identifying patients at risk of progression, assisting interpretation of uroflowmetry and imaging, and improving clinical-trial recruitment. Predictive tools may help clinicians compare expected benefits and adverse-effect risks across medication strategies when integrated with validated clinical data. Digital reminders and remote symptom tracking can reinforce adherence and identify treatment failure earlier. However, AI should remain an assistive capability: outputs require clinical validation, transparent data governance, protection of sensitive health information, and safeguards against demographic or socioeconomic bias. Evidence should demonstrate improved patient outcomes rather than relying solely on technical accuracy.

Regional Insights: Access, Diagnosis, and Treatment Capacity Vary Widely

North America generally benefits from broad access to primary care, urology services, prescription medicines, and minimally invasive treatment, although affordability, insurance design, and specialist availability remain important considerations. Europe combines established clinical guidance with diverse reimbursement systems and uneven access across countries. Asia-Pacific includes highly developed healthcare systems alongside rapidly expanding urban and specialist capacity, with diagnosis often shaped by aging populations and differences in health-seeking behavior. Latin America faces variation in public-sector resources, medicine access, and specialist coverage, making primary-care protocols and generic availability important. The Middle East is characterized by concentrated specialist capacity in major urban centers and differing reimbursement arrangements. Africa has substantial unmet need linked to limited diagnostic infrastructure, specialist shortages, delayed presentation, and medicine affordability; scalable primary-care screening and referral systems are particularly relevant.

Group Insights: Policy Alignment and Health-System Structure Shape Uptake

ASEAN members face diverse healthcare financing, regulatory, and specialist-capacity conditions, creating a need for adaptable treatment protocols and dependable medicine supply. BRICS countries combine large patient populations with marked differences in public coverage, domestic manufacturing, procurement, and urban-rural access. The European Union benefits from shared scientific and regulatory cooperation while retaining national differences in reimbursement and service delivery. G7 systems generally have mature diagnostic and pharmacological capabilities, but must address aging populations, polypharmacy, treatment adherence, and cost-effectiveness. GCC countries often have comparatively concentrated specialist services and strong urban infrastructure, while workforce distribution and reliance on imported medicines can affect continuity. NATO members span varied health systems, so interoperability of clinical guidance, medicine supply resilience, and preparedness for cross-border health pressures remain relevant.

Country Insights: National Contexts Create Different Priorities

Australia and Canada must balance extensive geographic coverage with timely access to primary care and urology services. Brazil and Mexico face regional disparities in public provision, diagnosis, and medicine availability. China and India have large and aging populations, with priorities including standardized diagnosis, tiered referral, and broader access beyond major cities. Japan and South Korea have advanced healthcare infrastructures and aging demographics, making treatment persistence, polypharmacy, and quality-of-life outcomes important. France, Germany, Italy, and Spain operate within established European systems but differ in reimbursement, prescribing practice, and waiting times. The United Kingdom emphasizes guideline-based care and primary-care management while managing referral capacity. The United States offers extensive therapeutic and procedural options, but insurance coverage, out-of-pocket costs, and fragmented care can influence treatment choice. Russia faces distinct challenges related to regional access, supply continuity, and specialist availability. Across all countries, clinicians must differentiate BPH symptoms from infection, neurogenic bladder, urethral obstruction, and prostate cancer.

Prioritize Evidence-Based Access, Adherence, and Integrated Care

Industry leaders should support therapies with clinically meaningful evidence on symptom improvement, urinary flow, progression risk, quality of life, persistence, and safety in older adults with comorbidities. Patient-centric packaging, plain-language education, adherence support, and shared-decision tools can improve appropriate use without encouraging unnecessary treatment. Organizations should work with health systems to strengthen primary-care algorithms, referral criteria, pharmacovigilance, and continuity of supply, while tailoring implementation to local reimbursement and regulatory requirements. Digital and AI-enabled services should be introduced only with validated endpoints, human oversight, cybersecurity controls, and transparent performance monitoring. Access strategies should include responsible generic competition, equitable distribution, and partnerships that improve diagnostic and treatment capacity in underserved areas.

Research Methodology: Evidence-Centered Market Assessment

This executive summary uses a structured review framework focused on the clinical and health-system dimensions of medication for benign prostatic hypertrophy. The assessment considers established disease-management pathways, recognized treatment classes, patient-selection factors, safety and adherence issues, diagnostic requirements, regulatory and reimbursement context, and differences in healthcare access across the specified regions, groups, and countries. Findings are framed qualitatively and avoid market estimates, market sizing, market shares, forecasts, and unsupported company-specific claims. Interpretation should be updated as clinical guidelines, comparative evidence, safety information, and national access policies change.

The Opportunity Is Better Coordinated, Patient-Centered BPH Management

Medication for benign prostatic hypertrophy remains most effective when embedded in a broader pathway that combines accurate assessment, individualized prescribing, monitoring, and timely escalation. The central priorities are improving diagnosis, preserving treatment adherence, managing adverse effects, and reducing inequities in access to primary and specialist care. Regional and national differences require flexible implementation rather than a single global model. Leaders that pair robust clinical evidence with responsible digital innovation, reliable supply, and health-system collaboration can help deliver safer, more continuous, and more patient-centered care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Benign Prostatic Hypertrophy Medication Market, by Product Type

  • 7.1. Introduction
  • 7.2. 5-Alpha Reductase Inhibitors
    • 7.2.1. Dutasteride
    • 7.2.2. Finasteride
  • 7.3. Alpha Blockers
    • 7.3.1. Alfuzosin
    • 7.3.2. Doxazosin
    • 7.3.3. Tamsulosin
    • 7.3.4. Terazosin
  • 7.4. Combination Therapies
    • 7.4.1. Dutasteride Tamsulosin
    • 7.4.2. Finasteride Tamsulosin

8. Benign Prostatic Hypertrophy Medication Market, by Drug Type

  • 8.1. Introduction
  • 8.2. Branded
  • 8.3. Generic

9. Benign Prostatic Hypertrophy Medication Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Benign Prostatic Hypertrophy Medication Market, by Age Group

  • 10.1. Introduction
  • 10.2. 45 to 64
  • 10.3. Above 65
  • 10.4. Below 45

11. Benign Prostatic Hypertrophy Medication Market, by Region

  • 11.1. Introduction
  • 11.2. Asia-Pacific
  • 11.3. North America
  • 11.4. Latin America
  • 11.5. Europe
  • 11.6. Middle East
  • 11.7. Africa

12. Benign Prostatic Hypertrophy Medication Market, by Group

  • 12.1. Introduction
  • 12.2. ASEAN
  • 12.3. GCC
  • 12.4. European Union
  • 12.5. BRICS
  • 12.6. G7
  • 12.7. NATO

13. Benign Prostatic Hypertrophy Medication Market, by Country

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. United Kingdom
  • 13.7. Germany
  • 13.8. France
  • 13.9. Russia
  • 13.10. Italy
  • 13.11. Spain
  • 13.12. China
  • 13.13. India
  • 13.14. Japan
  • 13.15. Australia
  • 13.16. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. Market Concentration Analysis, 2025
    • 14.2.1. Concentration Ratio (CR)
    • 14.2.2. Herfindahl Hirschman Index (HHI)
  • 14.3. Recent Developments & Impact Analysis, 2025
  • 14.4. Product Portfolio Analysis, 2025
  • 14.5. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. AbbVie Inc.
  • 15.2. Astellas Pharma Inc.
  • 15.3. Bayer AG
  • 15.4. Cipla Limited
  • 15.5. Dr. Reddy's Laboratories Ltd.
  • 15.6. Eli Lilly and Company
  • 15.7. Ferring Pharmaceuticals
  • 15.8. GlaxoSmithKline plc
  • 15.9. Lupin Limited
  • 15.10. Merck & Co., Inc.
  • 15.11. Novartis AG
  • 15.12. Pfizer Inc.
  • 15.13. Sanofi S.A.
  • 15.14. Sun Pharmaceutical Industries Ltd.
  • 15.15. Teva Pharmaceutical Industries Ltd.

16. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Benign Prostatic Hypertrophy Medication Market, Years Considered for the Study
  • FIGURE 2. Global Benign Prostatic Hypertrophy Medication Market, Research Design
  • FIGURE 3. Global Benign Prostatic Hypertrophy Medication Market, Research Framework
  • FIGURE 4. Global Benign Prostatic Hypertrophy Medication Market, Data Triangulation
  • FIGURE 5. Global Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2025 vs 2032 (%)
  • FIGURE 9. Global Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 11. Global Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2025 vs 2032 (%)
  • FIGURE 13. Global Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Benign Prostatic Hypertrophy Medication Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 15. Global Benign Prostatic Hypertrophy Medication Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Benign Prostatic Hypertrophy Medication Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 17. Global Benign Prostatic Hypertrophy Medication Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 18. Global Benign Prostatic Hypertrophy Medication Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global Benign Prostatic Hypertrophy Medication Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Benign Prostatic Hypertrophy Medication Market Segmentation & Coverage
  • TABLE 2. Global Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 4. Global 5-Alpha Reductase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global 5-Alpha Reductase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global 5-Alpha Reductase Inhibitors Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Dutasteride Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Dutasteride Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Dutasteride Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Finasteride Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Finasteride Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Finasteride Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Alpha Blockers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Alpha Blockers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Alpha Blockers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Alfuzosin Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Alfuzosin Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Alfuzosin Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Doxazosin Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Doxazosin Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Doxazosin Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Tamsulosin Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global Tamsulosin Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global Tamsulosin Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global Terazosin Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 26. Global Terazosin Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 27. Global Terazosin Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 28. Global Combination Therapies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 29. Global Combination Therapies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 30. Global Combination Therapies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 31. Global Dutasteride Tamsulosin Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 32. Global Dutasteride Tamsulosin Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 33. Global Dutasteride Tamsulosin Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 34. Global Finasteride Tamsulosin Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 35. Global Finasteride Tamsulosin Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 36. Global Finasteride Tamsulosin Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 37. Global Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 38. Global Branded Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 39. Global Branded Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 40. Global Branded Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 41. Global Generic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 42. Global Generic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 43. Global Generic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 44. Global Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 45. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 46. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 47. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 48. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 49. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 50. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 51. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 52. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 53. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 54. Global Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 55. Global 45 to 64 Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 56. Global 45 to 64 Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 57. Global 45 to 64 Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 58. Global Above 65 Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 59. Global Above 65 Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 60. Global Above 65 Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 61. Global Below 45 Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 62. Global Below 45 Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 63. Global Below 45 Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 64. Global Benign Prostatic Hypertrophy Medication Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 65. Asia-Pacific Benign Prostatic Hypertrophy Medication Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 66. Asia-Pacific Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 67. Asia-Pacific Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
  • TABLE 68. Asia-Pacific Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
  • TABLE 69. Asia-Pacific Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
  • TABLE 70. Asia-Pacific Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 71. Asia-Pacific Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 72. Asia-Pacific Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 73. North America Benign Prostatic Hypertrophy Medication Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 74. North America Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 75. North America Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
  • TABLE 76. North America Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
  • TABLE 77. North America Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
  • TABLE 78. North America Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 79. North America Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 80. North America Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 81. Latin America Benign Prostatic Hypertrophy Medication Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 82. Latin America Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 83. Latin America Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
  • TABLE 84. Latin America Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
  • TABLE 85. Latin America Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
  • TABLE 86. Latin America Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 87. Latin America Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 88. Latin America Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 89. Europe Benign Prostatic Hypertrophy Medication Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 90. Europe Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 91. Europe Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
  • TABLE 92. Europe Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
  • TABLE 93. Europe Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
  • TABLE 94. Europe Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 95. Europe Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 96. Europe Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 97. Middle East Benign Prostatic Hypertrophy Medication Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 98. Middle East Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 99. Middle East Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
  • TABLE 100. Middle East Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
  • TABLE 101. Middle East Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
  • TABLE 102. Middle East Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 103. Middle East Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 104. Middle East Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 105. Africa Benign Prostatic Hypertrophy Medication Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 106. Africa Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 107. Africa Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
  • TABLE 108. Africa Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
  • TABLE 109. Africa Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
  • TABLE 110. Africa Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 111. Africa Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 112. Africa Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 113. Global Benign Prostatic Hypertrophy Medication Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 114. ASEAN Benign Prostatic Hypertrophy Medication Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 115. ASEAN Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 116. ASEAN Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
  • TABLE 117. ASEAN Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
  • TABLE 118. ASEAN Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
  • TABLE 119. ASEAN Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 120. ASEAN Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 121. ASEAN Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 122. GCC Benign Prostatic Hypertrophy Medication Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 123. GCC Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 124. GCC Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
  • TABLE 125. GCC Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
  • TABLE 126. GCC Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
  • TABLE 127. GCC Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 128. GCC Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 129. GCC Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 130. European Union Benign Prostatic Hypertrophy Medication Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 131. European Union Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 132. European Union Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
  • TABLE 133. European Union Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
  • TABLE 134. European Union Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
  • TABLE 135. European Union Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 136. European Union Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 137. European Union Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 138. BRICS Benign Prostatic Hypertrophy Medication Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 139. BRICS Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 140. BRICS Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
  • TABLE 141. BRICS Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
  • TABLE 142. BRICS Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
  • TABLE 143. BRICS Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 144. BRICS Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 145. BRICS Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 146. G7 Benign Prostatic Hypertrophy Medication Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 147. G7 Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 148. G7 Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
  • TABLE 149. G7 Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
  • TABLE 150. G7 Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
  • TABLE 151. G7 Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 152. G7 Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 153. G7 Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 154. NATO Benign Prostatic Hypertrophy Medication Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 155. NATO Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 156. NATO Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
  • TABLE 157. NATO Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
  • TABLE 158. NATO Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
  • TABLE 159. NATO Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 160. NATO Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 161. NATO Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 162. Global Benign Prostatic Hypertrophy Medication Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 163. United States Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
  • TABLE 164. United States Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 165. United States Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
  • TABLE 166. United States Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
  • TABLE 167. United States Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
  • TABLE 168. United States Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 169. United States Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 170. United States Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 171. Canada Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
  • TABLE 172. Canada Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 173. Canada Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
  • TABLE 174. Canada Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
  • TABLE 175. Canada Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
  • TABLE 176. Canada Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 177. Canada Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 178. Canada Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 179. Mexico Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
  • TABLE 180. Mexico Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 181. Mexico Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
  • TABLE 182. Mexico Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
  • TABLE 183. Mexico Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
  • TABLE 184. Mexico Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 185. Mexico Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 186. Mexico Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 187. Brazil Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
  • TABLE 188. Brazil Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 189. Brazil Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
  • TABLE 190. Brazil Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
  • TABLE 191. Brazil Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
  • TABLE 192. Brazil Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 193. Brazil Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 194. Brazil Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 195. United Kingdom Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
  • TABLE 196. United Kingdom Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 197. United Kingdom Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
  • TABLE 198. United Kingdom Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
  • TABLE 199. United Kingdom Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
  • TABLE 200. United Kingdom Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 201. United Kingdom Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 202. United Kingdom Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 203. Germany Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
  • TABLE 204. Germany Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 205. Germany Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
  • TABLE 206. Germany Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
  • TABLE 207. Germany Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
  • TABLE 208. Germany Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 209. Germany Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 210. Germany Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 211. France Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
  • TABLE 212. France Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 213. France Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
  • TABLE 214. France Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
  • TABLE 215. France Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
  • TABLE 216. France Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 217. France Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 218. France Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 219. Russia Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
  • TABLE 220. Russia Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 221. Russia Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
  • TABLE 222. Russia Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
  • TABLE 223. Russia Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
  • TABLE 224. Russia Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 225. Russia Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 226. Russia Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 227. Italy Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
  • TABLE 228. Italy Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 229. Italy Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
  • TABLE 230. Italy Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
  • TABLE 231. Italy Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
  • TABLE 232. Italy Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 233. Italy Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 234. Italy Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 235. Spain Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
  • TABLE 236. Spain Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 237. Spain Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
  • TABLE 238. Spain Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
  • TABLE 239. Spain Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
  • TABLE 240. Spain Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 241. Spain Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 242. Spain Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 243. China Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
  • TABLE 244. China Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 245. China Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
  • TABLE 246. China Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
  • TABLE 247. China Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
  • TABLE 248. China Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 249. China Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 250. China Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 251. India Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
  • TABLE 252. India Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 253. India Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
  • TABLE 254. India Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
  • TABLE 255. India Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
  • TABLE 256. India Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 257. India Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 258. India Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 259. Japan Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
  • TABLE 260. Japan Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 261. Japan Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
  • TABLE 262. Japan Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
  • TABLE 263. Japan Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
  • TABLE 264. Japan Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 265. Japan Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 266. Japan Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 267. Australia Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
  • TABLE 268. Australia Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 269. Australia Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
  • TABLE 270. Australia Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
  • TABLE 271. Australia Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
  • TABLE 272. Australia Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 273. Australia Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 274. Australia Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 275. South Korea Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
  • TABLE 276. South Korea Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 277. South Korea Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
  • TABLE 278. South Korea Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
  • TABLE 279. South Korea Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
  • TABLE 280. South Korea Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 281. South Korea Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 282. South Korea Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 283. Global Benign Prostatic Hypertrophy Medication Market Share, by Key Player, 2025
  • TABLE 284. Global Benign Prostatic Hypertrophy Medication Market, Key Experts